Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Summary: Atherosclerotic cardiovascular disease and its thrombotic complications are the principal causes of morbidity and mortality in patients with type-2 diabetes.Aspirin reduces the risk of thrombotic events in a broad range of patients with vascular disease and, in selected individuals, is beneficial for primary prevention. Although recommended by existing guidelines,in secondary and in primary prevention trials the clinical efficacy of low-dose aspirin in patients with diabetes appears to be substantially lower than in individuals without diabetes. In this review, we discuss possible mechanisms that may contribute to reduce the antithrombotic activity of aspirin in diabetes.We also discuss adjuvant therapies used in diabetic patients that may potentially improve the antithrombotic efficacy of aspirin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ridker, P. M., Buring, J. E., Cook, N. R., & Rifai, N. (2003) · Circulation · doi:10.1161/01.cir.0000055014.62083.05 · Cited by 2,292
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720 · cited 1×
“12 Statins The beneficial effects of statins in the primary and secondary prevention of coronary heart disease have been demonstrated in several large-scale clinical trials (93).”
BackgroundRidker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Endothelial dysfunction in diabetes
De Vriese, A. S., Verbeuren, T. J., Van de Voorde, J., Lameire, N. H., & Vanhoutte, P. M. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703393 · Cited by 1,165 · cited 2×
“Not only high glucose concentrations per se, but also AGEs, which are increased in diabetic patients, induce a pro-inflammatory phenotype in endothelial cells, including upregulation of adhesive molecules (37, 48).”
BackgroundPeroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755 · cited 1×
“Thiazolidinediones (TZDs) Although initially identified as important regulators of metabolic processes in adipocytes and hepatocytes (118), recent experimental data established that activation of Peroxisome Proliferation Activated Receptors (PPARs) by natural or pharmacological ligands may switch off a number of infla…”
BackgroundThromboxane Biosynthesis and Platelet Function in Type II Diabetes Mellitus
Davì, G., Catalano, I., Averna, M., Notarbartolo, A., Strano, A., Ciabattoni, G., & Patrono, C. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006213222503 · Cited by 597
Davı̀, G., Gresele, P., Violi, F., Basili, S., Catalano, M., Giammarresi, C., Volpato, R., Nenci, G. G., Ciabattoni, G., & Patrono, C. (1997) · Circulation · doi:10.1161/01.cir.96.1.69 · Cited by 223
Niskanen, L., Hedner, T., Hansson, L., Lanke, J., Niklason, A., & for the CAPPP study group (2001) · Diabetes Care · doi:10.2337/diacare.24.12.2091 · Cited by 219
The Importance of Hyperglycemia in the Nonfasting State to the Development of Cardiovascular Disease
Haffner, S. M. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0343 · Cited by 193 · cited 1×
“Furthermore, a more than two-fold increased risk of CV events is already present in subjects with impaired glucose tolerance (IGT), that is normal fasting blood glucose levels and elevated values after oral glucose load (3).”
Background
Cited by
Kunutsor, S. K., Whitehouse, M. R., Blom, A. W., Beswick, A. D., & INFORM Team (2016) · PLOS ONE · doi:10.1371/journal.pone.0150866 · Cited by 479
De Berardis, G., Sacco, M., Strippoli, G. F. M., Pellegrini, F., Graziano, G., Tognoni, G., & Nicolucci, A. (2009) · BMJ · doi:10.1136/bmj.b4531 · Cited by 395
“An increasing amount of data suggest that factors specific to diabetes, including hyperglycaemia, hyperinsulinaemia, increased oxidative stress, and advanced glycosylation end products, may up-regulate humoral, cellular inflammatory, and thrombogenic reactions thereby playing a part in atherothrombosis.”
Self-citationStettler, C., Allemann, S., Wandel, S., Kastrati, A., Morice, M. C., Schomig, A., Pfisterer, M. E., Stone, G. W., Leon, M. B., Lezo, J. S. D., et al. (2008) · BMJ · doi:10.1136/bmj.a1331 · Cited by 320
“Again, this effect may be enhanced in people with diabetes, particularly in the absence of dual antiplatelet therapy. Moreover, overall longer stents in people with diabetes may result in a prolongation of the healing and re-endothelialisation process. Finally, people with diabetes may be more likely to experience asp…”
BackgroundThe Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood Pressure and Lipids
Dokken, B. B. (2008) · Diabetes Spectrum · doi:10.2337/diaspect.21.3.160 · Cited by 299
The Role of Aspirin in Cardiovascular Prevention
Gasparyan, A. Y., Watson, T., & Lip, G. Y. H. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.080 · Cited by 263
Metadata
- Authors
- Totani, L., Rotondo, S., Lorenzet, R., Tognoni, G., De Berardis, G., Nicolucci, A., & Evangelista, V.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2005
- Volume
- 93
- Issue
- 01
- Pages
- 8-16
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2155922543
- Cited by
- 57
- References
- 10
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.